Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-CD37 CAR T cells |
Synonyms | |
Therapy Description |
Anti-CD37 CAR T cells consist of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD37 and contains a CD8 transmembrane domain linked to CD137 (4-1BB) and CD3 zeta signaling domains, which potentially induces cytotoxicty against tumor cells expressing CD37, and reduces tumor burden (PMID: 30089630). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-CD37 CAR T cells | CAR-37 T cells|Anti-CD37-CAR-expressing T-lymphocytes | Anti-CD37 CAR T cells consist of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD37 and contains a CD8 transmembrane domain linked to CD137 (4-1BB) and CD3 zeta signaling domains, which potentially induces cytotoxicty against tumor cells expressing CD37, and reduces tumor burden (PMID: 30089630). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04136275 | Phase I | Anti-CD37 CAR T cells | CAR-37 T Cells In Hematologic Malignancies | Completed | USA | 0 |